Dr. Reddy’s Laboratories (NYSE:RDY) reported fiscal third-quarter revenue that surpassed analyst expectations Wednesday, as explosive growth in emerging markets and a resilient domestic business in India helped offset a steep decline in its North American generic portfolio.
Revelation Biosciences (NASDAQ:REVB) announced it has reached a milestone agreement with the FDA on an "expedient" approval pathway for Gemini, its lead candidate for the treatment of Acute Kidney Injury (AKI).
Lisata Therapeutics (NASDAQ:LSTA) shares soared Wednesday morning after the clinical-stage biotech announced a binding agreement to be acquired by privately held Kuva Labs.
Ionis Pharmaceuticals (NASDAQ:IONS) and Otsuka Pharmaceutical achieved a major regulatory victory Wednesday as the European Commission (EC) granted marketing authorization for DAWNZERA (donidalorsen).
Johnson & Johnson (NYSE:JNJ) shares rose Wednesday after the healthcare giant capped a record-breaking 2025 with a major fourth-quarter earnings beat and issued a bold 2026 forecast that projects annual sales exceeding the $100 billion mark for the first time.
Visionary Holdings (NASDAQ:GV) filed its audited financial statements for the fiscal year ended March 31, 2025, revealing a significant revenue decline as the company transitions away from its legacy education and real estate businesses toward a high-margin health and anti-aging platform.
Bristol Myers Squibb (NYSE:BMY) has partnered with Microsoft (NASDAQ:MSFT) to deploy artificial intelligence tools aimed at identifying lung cancer in its earliest stages, marking the latest push by a pharmaceutical giant to integrate big tech’s machine learning into clinical care.
Corvus Pharmaceuticals (NASDAQ:CRVS) shares skyrocketed more than 60% in early trading Tuesday after the company reported that its experimental oral therapy significantly cleared skin in patients with moderate-to-severe atopic dermatitis.
Viatris (NASDAQ:VTRS) has officially commenced the global expansion of its cardiovascular portfolio with the launch of Inpefa (sotagliflozin) in the United Arab Emirates, marking the first commercial availability of the therapy outside the United States.
Phio Pharmaceuticals (NASDAQ:PHIO) reported that its experimental gene-silencing therapy cleared tumors in the majority of patients during a mid-stage study, marking a significant win for its proprietary INTASYL technology.
Regentis Biomaterials (NYSE:RGNT) shares gained after new long-term imaging data showed its hydrogel implant successfully regenerated knee cartilage with a structural complexity nearly identical to healthy human tissue.
